"This study is genuinely exciting because it provides a rationale for considering such treatment routinely for patients with type 2 diabetes,” said Dr George Kassianos, a British GP and fellow of the European Society of Cardiology.
"It can save lives and reduce cardiovascular complications, regardless of whether patients have hypertension to start with or not - which has never been proven before," he added.
The study was carried out by an international group of independent medical researchers with support from Servier, which makes the drug.
Source-ANI
LIN/J